Lv6
2370 积分 2024-03-05 加入
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): an open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
26天前
已关闭
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)
5个月前
已完结
NEGATIVE MODULATORS OF THE CGAS-STING PATHWAY
6个月前
已完结
Discovery of N-Aryl-N′-[4-(aryloxy)cyclohexyl]squaramide-Based Inhibitors of LXR/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation
7个月前
已完结
Has Ferrocene Really Delivered Its Role in Accentuating the Bioactivity of Organic Scaffolds?
9个月前
已完结
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
1年前
已完结
American Society for Clinical Pharmacology and Therapeutics
1年前
已完结
A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315
1年前
已完结
SMALL-MOLECULE PROTEIN-PROTEIN INTERACTION MODULATORS (PPIm) OF THE IL-17 AND IL-17R COMPLEXES
1年前
已完结
皖公网安备34019202002308
